| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Across the recent three months, 6 analysts have shared their insights on Legend Biotech (NASDAQ:LEGN), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 4 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Legend Biotech and provided 12-month price targets. The average target is $75.83, accompanied by a high estimate of $83.00 and a low estimate of $66.00. This current average reflects an increase of 3.17% from the previous average price target of $73.50.
The standing of Legend Biotech among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jessica Fye | JP Morgan | Lowers | Overweight | $76.00 | $78.00 |
| Eric Schmidt | Cantor Fitzgerald | Raises | Overweight | $66.00 | $55.00 |
| Jessica Fye | JP Morgan | Raises | Overweight | $78.00 | $77.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $77.00 | $75.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $83.00 | $81.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $75.00 | $75.00 |
For valuable insights into Legend Biotech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Legend Biotech analyst ratings.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Legend Biotech displayed positive results in 3M. As of 30 June, 2025, the company achieved a solid revenue growth rate of approximately 36.74%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Legend Biotech's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -49.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Legend Biotech's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -12.21%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Legend Biotech's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.59%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Legend Biotech's debt-to-equity ratio is below the industry average at 0.37, reflecting a lower dependency on debt financing and a more conservative financial approach.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: LEGN
